Why This Seattle Biotech Could be an M&A Target Post author:Sam Post published:January 18, 2018 Post category:BioPharma Immune Design is a clinical-stage immunotherapy company. Source: BioSpace You Might Also Like Regulus Announces Pricing Of Public Offering Of Common Stock July 19, 2017 Co-Diagnostics To Undergo ISO 13485:2016 Audit August 9, 2017 Bay Area's Rani Therapeutics Lands $53M as Company Moves to Clinical Trials February 7, 2018
